Live Coverage
← Back to news

Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment

International homepage April 6, 2026 at 02:47 AM
Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment
Soleno Therapeutics makes first commercialised drug for extreme hunger caused by Prader-Willi syndrome

Original source

International homepage

Read Full Article